A-Alpha Bio Secures $20M Series A to Advance Yeast-Based Protein Interaction Platform

A-Alpha Bio raised $20 million in Series A funding and will apply its high-throughput yeast-based protein-protein interaction technology to drug discovery through partnerships with Twist Biopharma and Lumen Bioscience.

More: GeekWire, MedCity News

No comments yet.

Also discussed on the What Fuels You podcast